Inclusion Criteria:~* Diagnosis of probable Alzheimer Disease (AD) with documented evidence of progression of
disease~* Mini Mental State Examination (MMSE) score of 21-26, inclusive~* Clinical Dementia Rating global
score of 0.5 or 1~* Rosen-Modified Hachinski Ischemia Score less than or equal to 4~* Brain magnetic resonance
imaging (MRI) consistent with the diagnosis of probable AD~* Concurrent use of cholinesterase inhibitor or
memantine with stable dose for at least 3 months prior to randomization~* Caregiver willing to participate and
be able to attend clinic visits with patient~* Ability to ingest oral medications~
